CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (55,223,000)	$ (95,529,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,158,000	16,160,000
Amortization of inventory step-up	0	5,327,000
Allowance for credit losses and inventory reserves	619,000	398,000
Share-based compensation	37,502,000	23,779,000
Amortization of discount and cost of issuance of debt	516,000	500,000
Loss from change in fair value of warrants	0	22,286,000
Gain from change in fair value of contingent considerations and acquisition-related holdbacks	(32,690,000)	(673,000)
Loss from change in fair value of currency forward contract	1,209,000	0
Deferred tax liabilities	0	(3,716,000)
Amortization of right-of-use assets	1,656,000	1,196,000
Other	0	(43,000)
Changes in operating assets and liabilities:
Accounts receivable	5,459,000	(5,887,000)
Inventory	(5,772,000)	(15,476,000)
Accounts payable	5,654,000	(1,691,000)
Accrued expenses and other current liabilities	(4,415,000)	(7,716,000)
Accrued payroll liabilities	914,000	969,000
Prepaid and other current assets	(976,000)	(11,381,000)
Operating lease liabilities	(1,598,000)	(935,000)
Other long-term liabilities	(1,086,000)	(708,000)
Net cash used in operating activities	(29,073,000)	(73,140,000)
Cash flows from investing activities:
Purchases of property and equipment	(5,979,000)	(6,564,000)
Business combinations, net of cash acquired	(3,200,000)	(98,429,000)
Net cash used in investing activities	(9,179,000)	(104,993,000)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	2,318,000	53,135,000
Offering costs for the issuance of common stock/At-the-market offering	0	(1,137,000)
Proceeds from issuance of short-term debt obligations	10,404,000	0
Issuance costs on line of credit	(50,000)	0
Payments on debt obligations	(1,710,000)	(12,169,000)
Payments on financed software	(4,429,000)	(4,135,000)
Proceeds from exercise of stock options	25,000	31,000
Net cash provided by financing activities	6,558,000	35,725,000
Effect of exchange rate changes on cash and cash equivalents	2,663,000	1,189,000
Net decrease in cash and cash equivalents	(29,031,000)	(141,219,000)
Cash, cash equivalents and restricted cash at beginning of period	151,678,000	321,879,000
Cash, cash equivalents and restricted cash at end of period	122,647,000	180,660,000
Reconciliation of amounts on condensed consolidated balance sheet:
Cash and cash equivalents	112,347,000	180,660,000
Restricted cash	10,300,000	0
Total cash, cash equivalents and restricted cash	122,647,000	180,660,000
Supplemental disclosure of cash flow information:
Cash paid for interest	3,728,000	3,654,000
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	3,336,000	(649,000)
Fair value of common stock issued for business combination	0	85,391,000
Fair value of common stock issuable for business combination	0	20,979,000
Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks	47,211,000	0
Contingent consideration for business combination	4,599,000	73,072,000
Accrual for purchase consideration for business combination	1,300,000	4,264,000
Fair value of common stock issued for investment in Expedera	$ 3,428,000	$ 0